Heart Failure

NEW ORLEANS — In the STOP-CA trial, prophylactic atorvastatin therapy reduced the occurrence of anthracycline-associated left ventricular dysfunction at 12 months among patients who underwent treatment for Hodgkin and non-Hodgkin lymphoma.

For every 500 extra steps per day, or an additional one-quarter mile walked, adults aged 70 years or older could reduce risk for a CVD event by approximately 14%, a speaker reported.

In patients with HF, mesenchymal precursor cell therapy reduced risk for MI and stroke, especially in those with systemic inflammation, but did not meet the primary endpoint of improvement in recurrent nonfatal decompensated HF events.

High-quality sleep was associated with a reduced mortality risk, according to data presented at the American College of Cardiology Scientific Session.

The benefit of dapagliflozin was consistent among adults with HF with and without gout and was associated with reduced initiation of new treatments for hyperuricemia and gout, according to a post hoc analysis of DAPA-HF and DELIVER.

Rheumatoid arthritis is independently associated with incident HF across the range of ejection fraction, with a stronger association among those with an EF of at least 40%, researchers reported.

Emerging precision medicine therapies targeting the molecular causes of cardiomyopathy and HF may improve the outlook for pediatric patients with HF, according to a review published in Translational Pediatrics.

Adults with HF after hospitalization for STEMI have lower serum iron levels compared with those without HF after STEMI, data from a retrospective case-control study show.

Remote patient management vs. usual care for time to all-cause death or rehospitalization in acute HF.

The prevalence of HF in the adult population is 1% to 2%, according to a meta-analysis of populations from 11 countries published in Heart.